CC BY-NC-ND 4.0 · World J Nucl Med 2020; 19(01): 15-20 DOI: 10.4103/wjnm.WJNM_20_19
Original Article
Potential application of lutetium-177-labeled prostate-specific membrane antigen-617 radioligand therapy for metastatic castration-resistant prostate cancer in a limited resource environment: Initial clinical experience after 2 years
Majid Assadi
Department of Molecular Imaging and Radionuclide Therapy (MIRT), The Persian Gulf Nuclear Medicine Research Center, Bushehr University of Medical Sciences, Bushehr
,
Samira Rezaei
Department of Molecular Imaging and Radionuclide Therapy (MIRT), The Persian Gulf Nuclear Medicine Research Center, Bushehr University of Medical Sciences, Bushehr
,
Esmail Jafari
Department of Molecular Imaging and Radionuclide Therapy (MIRT), The Persian Gulf Nuclear Medicine Research Center, Bushehr University of Medical Sciences, Bushehr
,
Seyed Javad Rekabpour
1
Department of Oncology, Bushehr Medical University Hospital, Bushehr University of Medical Sciences, Bushehr
,
Mohammad Ravanbod
1
Department of Oncology, Bushehr Medical University Hospital, Bushehr University of Medical Sciences, Bushehr
,
Farshad Zohrabi
2
Department of Urology, Bushehr Medical University Hospital, Bushehr University of Medical Sciences, Bushehr
,
AbdulLatif Amini
3
Department of Cardiology, Bushehr Heart Medical Center, Bushehr University of Medical Sciences, Bushehr
,
Saeid Keshmiri
4
Department of Anesthesiology (Division of Pain Management), Bushehr Heart Medical Center, Bushehr University of Medical Sciences, Bushehr
,
Habibollah Dadgar
5
Cancer Research Center, RAZAVI Hospital, Imam Reza International University, Mashhad, Iran
,
Hojjat Ahmadzadehfar
6
Department of Nuclear Medicine, University Hospital Bonn, Sigmund-Freud-Str. 25, 53127 Bonn, Germany